Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer-Reference-Cited by-同舟云学术

Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer

Published:2012-08 Issue:2 Volume:77 Page:359-364
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Spigel David R.,Greco F. Anthony,Rubin Mark S.,Shipley Dianna,Thompson Dana S.,Lubiner Eric T.,Eakle Janice F.,Quinn Raven,Burris Howard A.,Hainsworth John D.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference44 articles.

1. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer;Schmittel;Ann Oncol,2006

2. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer;Noda;N Engl J Med,2002

3. S0124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC);Natale;J Clin Oncol (Meeting Abstracts),2008

4. Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer;Kinoshita;Brit J Cancer,2006

5. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial;Hermes;J Clin Oncol,2008

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Stable Irinotecan Liposome with Enhanced Antitumor Activity in a Range of Tumor Models;Pharmaceutical Research;2023-11-01

2. Novel Therapeutic Options for Small Cell Lung Cancer;Current Oncology Reports;2023-10-23

3. Lung cancer immunotherapy: progress, pitfalls, and promises;Molecular Cancer;2023-02-21

4. Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification;Lung Cancer;2023-01

5. Small cell lung cancer: an overview of the targets;Brazilian Journal of Pharmaceutical Sciences;2022